The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution.
This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.
Age of 4 to 17 (Chinese only);
With EASI ≥ 10;
Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and
Provide written informed consent form (signed by one of their parents)
History of allergy to Chinese medicines;
AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence
Known overt bacterial infections in the skin;
Known pregnancy;